Tempus AI Shares Plunge 2.11% Amid Legal Scrutiny Trading Volume Ranks 313th

Tempus AI (TEM) fell 2.11% on July 31, 2025, with a trading volume of $0.46 billion, ranking 313th in daily market activity. The decline followed renewed scrutiny over its financial disclosures and business practices, as multiple legal actions highlighted alleged misrepresentations.

Two law firms have filed class-action lawsuits against Tempus, alleging securities fraud. The suits claim the company inflated contract values, including agreements with related parties and self-funded deals, while downplaying risks tied to its joint ventures. A partnership with SoftBank was criticized for potentially "round-tripping" capital to artificially boost revenue. Additionally, Tempus’s acquisition of Ambry was scrutinized for aggressive billing practices, and its collaboration with AstraZeneca was alleged to involve a questionable "pass-through payment" structure. These practices, the lawsuits argue, led to misleading public statements about the company’s financial health.

Investors who purchased Tempus shares between August 2024 and May 2025 are being invited to join the lawsuits. Legal representatives emphasize that the alleged misstatements created a false impression of operational strength, causing damages when market realities emerged. The cases remain un-certified, with plaintiffs advised to act by August 12, 2025.

A backtested trading strategy involving the top 500 high-volume stocks yielded a 166.71% return from 2022 to July 30, 2025, significantly outperforming a benchmark index’s 29.18% return. The approach’s success was attributed to capturing momentum in liquid stocks, reflecting broader market dynamics where high-volume equities often drive price movements. This underscores the interplay between liquidity, investor sentiment, and short-term returns in today’s markets.